She is passionate about viable circulating tumour cells (CTC), drug discovery, and gene therapeutics in human clinical trials. Keen to apply the lab developed technology to radiotherapy cancer care, cure, and prevention strategies. She is optimistic about developing and executing interstate, interdisciplinary research collaborations of five countries strategies. 

Currently, bridging SFRP4 cancer stem cells, drug discovery gap to the new generation SFRP4 producing circulating cancer stem cell (CCSC) therapeutics. 

She is way to conducting global clinical trials roles with top-class government hospital training in preclinical radio theranostics, attracting ArcherDX merit research grant of 20 000 USD, extramural research income of 403 000 AUD and intramural 25 000 AUD funding. Previously, she has worked with the Indian premier central government research Institute, deemed University, Perth Curtin University cross departments and faculties, Australia interstate University, Oxford University London UK, UCSD USA, and Swiz radiation oncology department, University of Berne. 

She has significant experience conducting diverse (phase 1) CTC clinical trials in Australia and writing successful research grants/business models for SCGH hospital, ArcherDX India-Chennai, Sri Ramachandra Institute of higher education-USA collaborations, global Merck and managing research students and staff by providing research methods training. Dr Vanathi also has varied experience in molecular biology and cancer cell signalling. She focuses on innovative therapeutics with medical device components for radiotherapy, chemotherapy, and gene therapies in a stringent budget with well-advanced timelines.

Dr Vanathi holds a PhD in mesothelioma cancer biology from Curtin University Perth, WA. She obtained her Master’s degree in zoology from Annamalai University, a Diploma in biotechnology and a Bachelor of Science degree from Madurai Kamaraj University India.

Since 1995-2021 with diversity inclusion, contributed to twenty peer-reviewed publications, thesis, and manuscripts as first, co-author and lead author, including thirty-one national, international conference/symposium/workshop in-person and virtual proceedings. She is a reviewer of spandidos and cancers journals. Fluent in English, Tamil, Hindi, and Telugu. 

Grants: three with two success rates. 

Patents: Three CTC products under development. 

Professional bodies: Science on the Swan, EMBO, AACR. 

Awards: Global health care award, Indian achiever forum -international achiever and woman of excellence award, SCGH clinical research fellow, CIPRS, ATN travel award and Swiz radiation oncology fellow.

She promises to lead the cancer science legacy with integrity, passion, and commitment. In serving the cancer community aspires to improve quality of life by delivering less invasive, less side effects, more accuracy faster turnaround diagnostic products. She is highly motivated to receive future global awards securing a sound funding track with high-quality publications for world-class cancer treatments strategically for a sustainable future in a holistic way for the future generation.